×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ADCT – adc therapeutics sa common shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ADCT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/4
07:57 am
adct
ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma [Yahoo! Finance]
Medium
Report
ADC Therapeutics updates data from Phase 1b trial of Zynlonta in lymphoma [Yahoo! Finance]
12/3
03:13 pm
adct
ADC Therapeutics (NYSE:ADCT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
High
Report
ADC Therapeutics (NYSE:ADCT) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
12/3
11:03 am
adct
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript [Seeking Alpha]
High
Report
ADC Therapeutics SA (ADCT) Discusses Updated Results From LOTIS-7 Trial Evaluating ZYNLONTA Plus Glofitamab in Relapsed or Refractory DLBCL Transcript [Seeking Alpha]
12/3
07:53 am
adct
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma [Yahoo! Finance
High
Report
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma [Yahoo! Finance
12/3
07:30 am
adct
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
High
Report
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
12/2
04:26 pm
adct
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial [Yahoo! Finance]
High
Report
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial [Yahoo! Finance]
12/2
04:05 pm
adct
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
High
Report
ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial
12/1
04:05 pm
adct
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Medium
Report
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Date
Time
Symbol
Company Name
Action
%Chg
11/10/2025
07:30 am
adct
adc therapeutics sa common shares
BEAT
Report
3.4%
adc therapeutics sa common shares
8/12/2025
07:30 am
adct
adc therapeutics sa common shares
BEAT
Report
0.0%
adc therapeutics sa common shares
5/14/2025
08:00 am
adct
adc therapeutics sa common shares
BEAT
Report
29.3%
adc therapeutics sa common shares
3/27/2025
07:30 am
adct
adc therapeutics sa common shares
BEAT
Report
-1.9%
adc therapeutics sa common shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/13
07:39 pm
adct
Form SCHEDULE 13G/A ADC Therapeutics SA Filed by: Prosight Management, LP
Low
Report
Form SCHEDULE 13G/A ADC Therapeutics SA Filed by: Prosight Management, LP
11/10
04:33 pm
adct
Form 10-Q ADC Therapeutics SA For: Sep 30
Medium
Report
Form 10-Q ADC Therapeutics SA For: Sep 30
11/10
08:18 am
adct
Form 8-K ADC Therapeutics SA For: Nov 10
Low
Report
Form 8-K ADC Therapeutics SA For: Nov 10
11/5
04:05 pm
adct
Form SCHEDULE 13G/A ADC Therapeutics SA Filed by: Oaktree Capital Group Holdings GP, LLC
Medium
Report
Form SCHEDULE 13G/A ADC Therapeutics SA Filed by: Oaktree Capital Group Holdings GP, LLC
10/28
09:00 pm
adct
Form 4 ADC Therapeutics SA For: Oct 27 Filed by: Redmile Group, LLC
Medium
Report
Form 4 ADC Therapeutics SA For: Oct 27 Filed by: Redmile Group, LLC
10/14
06:16 am
adct
Form 8-K ADC Therapeutics SA For: Oct 12
High
Report
Form 8-K ADC Therapeutics SA For: Oct 12
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: